Target

PI3Kδ

Aliases

PI3K

37 products, 19 indications

Indications

Metastatic Castration-Resistant Prostate Cancer (22 products)

metastatic castration-sensitive prostate cancer (7 products)

metastatic hormone sensitive prostate cancer (7 products)

non-metastatic castration-resistant prostate cancer (6 products)

Advanced or metastatic prostate cancer (4 products)

Prostate cancer (3 products)

metastatic hormone-naive prostate cancer (3 products)

de novo metastatic castration-sensitive prostate cancer (2 products)

Low-risk prostate cancer (2 products)

recurrent prostate cancer (2 products)

glioblastoma (1 products)

PSA-recurrent, non-metastatic, non-castrate prostate cancer (1 products)

Prostate cancer with COVID-19 (1 products)

hormone-naive prostate cancer with pelvic lymph node metastases (1 products)

Metastatic CSPC (1 products)

stage IIB/C melanoma (1 products)

recurrent or metastatic cervical cancer (1 products)

recurrent or metastatic head and neck squamous cell carcinoma (1 products)

Newly diagnosed glioblastoma or anaplastic astrocytoma (1 products)

4 drugs

7 abstracts

Abstract

Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).

Org: Beigene Netherlands B.V., The Alfred and Monash University,

Abstract

Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.

Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy, iOnctura SA, Geneva, Switzerland, iOnctura, Geneva, Switzerland, Covance Clinical and Peri-approval Services LTD, Milano, Italy,

Abstract

In silico design of novel multitarget small molecule inhibitors to treat PTEN-mutant endometrial carcinoma.

Org: Molecular Targeted Therapeutics Laboratory,

Abstract

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.

Org: LTD High Technology Hospital Med Center, Batumi, Georgia, LLC Caucasus Medical Center, Simon Khechinashvili University Hospital, Rhizen Pharmaceuticals AG,

Abstract

First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

Org: iOnctura SA, Geneva, Switzerland, iOnctura, Covance Clinical and Peri-approval Services LTD, Milano, Italy, Radiomics, Liege, Belgium,

Abstract

A phase 1a/b study of BR101801, a PI3K γ/δ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.

Org: Boryung Corporation, Samsung Medical Center, Seoul National University Cancer Research Institute, Seoul, Republic of Korea, Seoul National University Hospital, Asan Medical Center,

Abstract

Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.

Org: University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA, Washington University School of Medicine in St Louis, St. Louis, MO, Department of Immunology and Oncology, Clínica Universidad de Navarra,

Drug

Drug

Drug

Drug